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ABSTRACT
Background: The presence of direct-acting antiviral (DAA) has improved the treatment of hepatitis C virus 
(HCV) infection and making it more preferable than Pegylated-interferon (PegIFN) and Ribavirin (RBV) based 
treatment. However, treatment with all DAA combination regimen is limited and expensive in low health care 
affordability country including Indonesia. The appearance of generic sofosbuvir (SOF) facilitate the utilization 
of SOF plus PegINF with or without RBV combination. Therefore, in this study we assessed the efficacy of 
SOF+RBV and SOF+RBV+PegINF combination for treatment of chronic hepatitis C infections patient with 
genotype 1 in Indonesia.
Method: We performed retrospective study comprising 128 patients in Cipto Mangunkusumo Hospital with 
chronic hepatitis C, genotype 1, infection. Thirty six (36) patients was treated with PegINF+SOF+RBV and 
92 patients was treated with SOF+RBV with the duration of therapy was 12 and 24 weeks in both arms. The 
primary endpoint was sustained virologic response after treatment completion (SVR12).
Results: In the end of treatment, 99.2% patients achieved undetected HCV RNA in 12 weeks and 24 weeks 
duration of therapy (100% in PegINF+SOF+RBV group and 98.9% in SOF+RBV group). The SVR12 of 
PegINF+SOF+RBV reach 100% meanwhile The SVR12 of SOF+RBV reach 88%. No different in SVR12 between 
cirrhotic and non-cirrhotic patient in PegINF+SOF+RBV group while in SOF+RBV group, the SVR12 was 
lower in cirrhotic patients (82.9%) compared to non-cirrhotic patients (92.2%). In multivariate analysis, HIV 
co-infection is associated with lower SVR12 in SOF+RBV group.
Conclusion: Twelve (12) weeks and 24 weeks of PegINF+SOF+RBV and SOF+RBV is effective in the 
treatment of genotype 1 chronic hepatitis C infection.
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ABSTRAK
Latar belakang: Pemberian direct-acting antiviral (DAA) meningkatkan keberhasilan pengobatan infeksi 
virus hepatitis C (VHC). Dengan efikasi yang lebih tinggi dan efek samping yang minimal, DAA lebih dipilih 
dibandingkan dengan kombinasi Pegylated-interferon (PegIFN) dan Ribavirin (RBV). Namun kombinasi DAA 
seluruhnya masih terbatas dan mahal terutama di Indonesia. Sofosbuvir merupakan salah satu DAA yang tersedia 
dalam bentuk generik dan dapat dikombinasi dengan PegIFN dan RBV. Penelitian ini bertujuan untuk menilai 
efikasi kombinasi SOF+RBV dan SOF+RBV+PegINF pada infeksi VHC genotipe 1 di Indonesia.
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Metode: Kami melakukan studi retrospektif terhadap 128 pasien infeksi VHC genotipe 1 di Rumah Sakit Cipto 
Mangunkusumo. Tiga puluh enam (36) pasien mendapatkan PegINF+SOF+RBV dan 92 pasien mendapatkan 
SOF+RBV dengan durasi terapi selama 12 dan 24 minggu pada kedua kelompok studi. Pemeriksaan muatan 
virus (HCV RNA) dilakukan pada saat selesai terapi (EOT) dan 12 minggu setelah selesai terapi (SVR12).
Hasil: Pada EOT 12 dan 14 minggu, HCV RNA tidak terdeteksi pada 99.2% pasien (100% pada kelompok 
PegINF+SOF+RBV dan 98.9% pada kelompok SOF+RBV). SVR12 pada kelompok PegINF+SOF+RBV mencapai 
100% sementara pada kelompok SOF+RBV mencapai 88%. Tidak ada perbedaan SVR12 secara bermakan antara 
pasien dengan atau tanpa sirosis pada kelompok PegINF+SOF+RBV sedangkan pada kelompok SOF+RBV, 
SVR12 pasien dengan sirosis lebih rendah dibandingkan dengan pasien non-sirosis (82.9% vs. 92.2%). Pada 
analisis multivariat, ko-infeksi HIV dihubungkan dengan SVR12 yang lebih rendah pada kelompok SOF+RBV.
Simpulan: Pemberian terapi PegINF+SOF+RBV dan SOF+RBV selama 12 serta 24 minggu efektif terhadap 
infeksi VHC genotipe 1.
Kata kunci: direct-acting antiviral, hepatitis C, sofosbuvir, ribavirin, interferon
INTRODUCTION
Chronic hepatitis C is a major health problem in 
the world. According to WHO, 3% people is infected 
worldwide with the prevalence is around 180 million 
people.1 Hepatitis C infection is also a major health 
problem in Indonesia. The Indonesia Health Survey 
2013 estimated that 2.5% of Indonesia People infected 
with hepatitis C.2 Untreated hepatitis C virus infection 
will increase the risk of chronic liver diseases, cirrhosis, 
and liver cancer or hepatocellular carcinoma (HCC).3
HCV is a positive-stranded RNA-enveloped virus 
with six major genotypes (GTs). GT1 is the most 
common HCV genotype in the world comprising 
46.2% of total HCV cases.4 The similarity is also 
shown in Indonesia’s HCV patient that GT1 being the 
most common HCV genotype. Furthermore, the core 
sequencing reveal that GT1b was the most common 
HCV subtype with 47.3% followed by subtype 1c with 
18.7%.5 The treatment of HCV infection has improved 
remarkably in the presence of direct-acting antiviral 
(DAA). Prior pegylated interferon based treatment has 
become obsolete compare to all-oral DAA treatment 
with higher sustain virologic response (SVR) rate 
and lower side effects.6 Unfortunately, DAA based 
treatment is limited and expensive in low health care 
affordability country including in Southeast Asia.7 This 
cause Pegylated interferon (PegINF) and Ribavirin 
(RBV) based treatment is still maintained. 
However, several selected Asian Country, including 
Indonesia, has opportunity to use generic DAA 
sofosbuvir with more affordable price. Sofosbuvir 
(SOF) is a HCV NS5B polymerase inhibitor that 
was recently approved for treatment of chronic HCV 
genotypes 1 to 4. Addition SOF to RBV with or 
without PEG will improve the SVR rate up to 50-90%.8 
Nonetheless, with majority of genotype 1 infections, 
the combination of SOF with PEG/RBV is no longer 
mentioned in some of the guidelines where other 
DAAs combination is more favorable for genotype 1, 
such as sofosbuvir/ledipasvir combination.9 Despite 
no longer stated in the recent guideline, combination 
of SOF+RBV with or without PegINF are remain 
used in treatment of chronic HCV with genotype 1 
in Indonesia. With limited study available for this 
regiment particularly for genotype 1, we concluded 
that further study is needed. Therefore, in this 
study we assessed the efficacy of SOF+RBV and 
SOF+RBV+PegINF combination for treatment of 
chronic hepatitis C infections patient with genotype 
1 in Indonesia.
METHOD
We performed retrospective cohort study of 
patients ≥ 18 years of age diagnosed with HCV 
genotype 1 infection at the hepatobiliary clinic, Cipto 
Mangunkusumo Hospital, between 2016 and 2017. 
Treatment-naive and treatment experienced who 
received Sofosbuvir plus Ribavirin and Sofosbuvir 
plus Pegylated interferon and Ribavirin were included 
in this study. 
Patient’s data were collected from hospital health 
record including patient demographics, baseline 
laboratory data, treatment history, presence of cirhosis, 
HCV genotype and baseline HCV-RNA. Cirrhosis was 
diagnosed by biopsy or by transient elastography (> 
12.5 kPa). Patients with initial viral load more than 8 x 
105 IU/mL were considered as high viral load. Patient 
data were followed retrospectively through treatment 
duration. HCV RNA data at the end of treatment (EOT) 
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duration were collected. The primary point of this study 
are the absence of detectable HCR RNA in serum 12 
week (SVR12) and 24 week (SVR24) after treatment 
duration. Patients whose data were not complete were 
considered as lost-to-follow-up. Any discharge of 
therapy due to adverse events and death were reported. 
This study was approved by the Institutional Review 
Board at Faculty of Medicine Universitas Indonesia 
(No. Protocol: 17-12-1208).
Univariate analysis were performed to identify 
factors associated with SVR12. Variables which 
included in univariate analysis were patient’s 
demographic characteristic, HIV and HBV co-
infections, cirrhosis, and baseline viral load. A p 
< 0.05 was considered statistically significant. All 
analysis was performed using SPSS version 22 (IBM 
Corporation, New York, NY).
RESULTS
From 2016 through 2017, 128 patients were 
enrolled in this study. Thirty six (36) patients were 
received SOF+RBV+PEG IFN and 92 patients received 
SOF+RBV. Seventy four (74) patients (57.8%) were 
male and mean age of all participants was 53. All patients 
were Asians with 96.1% were Chinese and 3.9% were 
Indonesian. Median initial viral load of all regimens 
was 1.53 x 106. Initial high viral load was identified 
in 80.6% in SOF+RBV+PEG INF group and 58.7% 
in SOF+RBV group. In sub genotype analysis, most 
of the patients had genotype 1 who’s the sub genotype 
had not been identified and labeled as undeterm. Sub 
genotype 1b and 1a followed by 28.1% and 24.2%. 
Forty eight (48) patients were cirrhotic that 7 patients 
in SOF+RBV+PEG IFN group and 41 patients in SOF 
+ RBV group. Total 4 patients had HIV co-infection, 1 
patient in SOF+RBV+PEG IFN group and 3 patients in 
SOF+RBV group. In SOF+RBV+PEG IFN group, 28 
patiens (77.8%) had 12 weeks of treatment duration and 
8 patients (22.2%) in 24 weeks. In SOF+RBV group, 
44 patients (47.8%) had 12 weeks of duration and 48 
patients (52.2%) in 24 weeks (Table 1).
In the end of treatment (EOT), 99.2% patients 
achieved undetected HCV RNA in 12 weeks and 24 
weeks duration of therapy (100% in PegINF+SOF+RBV 
group and 98.9% in SOF+RBV group). All 36 (100%) 
patients treated with SOF+RBV+PegIFN reached 
SVR12 meanwhile 81/92 patients (88%) treated with 
SOF+RBV reached SVR12. Overall SVR12 of patients 
with HCV genotype 1 treated with combination of SOF 
plus RBV with/without PegIFN were 91.4% (Figure 1). 
In multivariate analysis, HIV co-infection is associated 
with lower SVR in SOF+RBV group (OR = 0.05; 
95% CI = 0.01-0.67) where all the 3 HIV co-infected 
patients failed to reach SVR12 (Table 2).
Table 1. Characteristic demographic and clinical baseline 
patients hepatitis C genotype 1 
Overall
(n = 128)
SOF + RBV 
+ PEG IFN
(n = 36)
SOF + RBV 
(n = 92)
Demographic
Number of patients 
(%)
128 (100%) 36 (28.1%) 92 (71.9%)
Male sex – n (%) 74 (57.8%) 27 (75%) 47 (51.1%)
Age – mean (range) 53 (27-82) 42 (32-74) 58 (27-82)
Race, n (%)
 Indonesian 123 (96.1%) 35 (97.2%) 88 (95.7%)
 Chinese 5 (3.9%) 1 (2.8%) 4 (4.3%)
Clinical Baseline
Initial Viral load IU/ 
mL – median (range)
1.53 x 106
(6.5 x 101 – 
5.7 x 109)
2.51 x 106
(1.9 x 102 – 
2.9 x 107)
1.53 x 106
(6.5 x 101 – 
5.7 x 109)
Initial High Viral load 
IU/ mL – n (%)
83 (64.8%) 29 (80.6%) 54 (58.7%)
Sub Genotype, n (%)
 1a 31 (24.2%) 8 (22.2%) 23 (25%)
 1b 36 (28.1%) 10 (27.8%) 26 (28.3%)
 1c 5 (3.9%) 2 (5.6%) 3 (3.3%)
 1d 1 (0.8%) 0 (0%) 1 (1.1%)
 Undeterm 1 55 (43%) 16 (44.4%) 39 (42.4%)
Median AST (range) 
– U/L
59 (17-395) 59 (17-191) 59 (20-395)
Median ALT  
(range) – U/L
62 (8-303) 62 (8-303) 62 (11-228)
Presence of 
Cirrhosis – n (%)
48 (37.5%) 7 (19.4%) 41 (44.6%)
Presence of HIV – n 
(%)
3 (2.3%) 1 (2.8%) 2 (2.1%)
Duration of 
Treatment, n (%)
 12 weeks 72 (56.3%) 28 (77.8%) 44 (47.8%)
 24 weeks 56 (43.8%) 8 (22.2%) 48 (52.2%)
Table 2. Bivariate analysis baseline characteristics of SVR in 
sofosbuvir plus ribavirin group
Baseline characteristic Odds ratio (OR)
95% 
confidence 
Iinterval
p
Gender: male vs. female 1.79 (0.48–6.60) 0.524
Age: ≥ 40 vs. <40 0.31 (0.04-2.53) 0.446
Low viral Load vs. high 
viral load
2.82 (0.76-10.43) 0.190
Cirrhosis 0.41 (0.11-1.52) 0.208
HIV co-infection 0.1 (0.05-0.19) 0.013
   Undeterm 1 55 (43%) 16 (44.4%) 39 (42.4%) 
Median AST (range) – U/L 59 (17-395) 59 (17-191) 59 (20-395) 
Median ALT (range) – U/L 62 (8-303) 62 (8-303) 62 (11-228) 
Presence of Cirrhosis – n (%) 48 (37.5%) 7 (19.4%) 41 (44.6%) 
Presence of HIV – n (%) 3 (2.3%) 1 (2.8%) 2 (2.1%) 
Duration of Treatment, n (%)    
   12 weeks 72 (56.3%) 28 (77.8%) 44 (47.8%) 
   24 weeks 56 (43.8%) 8 (22.2%) 48 (52.2%) 
Table 2. Bivariate analysis baseline characteristics of SVR in sofosbuvir plus ribavirin group 
Baseline characteristic Odds Ratio 
(OR) 
95% Confidence 
Interval 
p 
Gender: male vs. female 1.79  (0.48–6.60) 0.524 
Age: ≥ 40 vs. <40 0.31 (0.04-2.53) 0.446 
Low viral Load vs. high viral load 2.82 (0.76-10.43) 0.190 
Cirrhosis 0.41 (0.11-1.52) 0.208 
HIV co-infection 0.1 (0.05-0.19) 0.013 
Figure 1. Undetectable HCV RNA in the end of treatment (EOT) and SVR12 
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DISCUSSION
In this study, combination of Sofosbuvir plus 
ribavirin with/without PegIFN for 12 and 24 weeks 
led to high rates of sustained virological response in 
patients with HCV genotype 1 infection. Regimen of 
Sofosbuvir plus Ribavirin plus PegIFN show excellent 
effectiveness with 100% of SVR12 rate including 
patients with high intial viral load, cirrhosis, and 
HIV co-infections regardless the duration of therapy. 
Nonetheless, combination Sofosbuvir and Ribavirin 
also showed high rates of SVR12 with 88%.
This study shows that the combination of Sofosbuvir 
plus Ribavirin had high SVR12 of 88% and 98.9% 
undetected of HCV RNA in the end of treatment. 
No significant different in duration of therapy with 
12 weeks and 24 weeks as well as cirrhosis status 
of the patients. However, Sofosbuvir and Ribavirin 
treatment has less effectiveness in patients with HIV 
co-infections which all 3 patients failed to reach 
SVR12. Study by Lai et al showed excellent SVR of 
Sofosbuvir plus Ribavirin in Asian population with 
HCV genotype 1 infection. Twenty (20) patient with 
HCVgenotype 1b infection treating with Sofosbuvir 
plus Ribavirin achieved high rates of SVR12, 100% 
for 12 and 16 weeks therapy and 83% with 24 weeks 
therapy.10
Another study comprising sofosbuvir with Ribavirin 
in HCV genotype 1 patients by Gane et al showed 
relatively high SVR24 weeks in treatment-naive 
patients with 84% (21/25). However, this regiment 
is less effective with treatment-experienced patients 
that only 10% achieved SVR24.11 Compared to HCV 
genotype 2 and 3, Sofosbuvir plus Ribavirin showed 
less efficacy in genotype 1 in achieving SVR24 yet all 
groups showed similar viral kinetics characteristic that 
all patients had an undetectable level of HCV RNA 
by week 4. This identical virologic response in all 
treatment groups was showed regardless of genotype, 
treatment history, baseline viral load, race, ethnic 
group, IL28B status, and presence of interferon in 
regimen. However, in genotype 1 HCV and treatment 
experienced patients, this virologic response did not 
sustain.
However, combination of sofosbuvir and ribavirin 
for genotype 1 showed less effectiveness with SVR 
range from 47% to 84% in various study.12,13 A 
randomized clinical trial study by Osinusi et al show 
the efficacy and safety of sofosbuvir with weight-based 
or low-dose ribavirin with 60 treatment-naive hepatitis 
C genotype 1 patients. The SVR24 of this study are 
68% for weight-based and 48% for low-dose Ribavirin. 
This study identified association between male sex, 
advanced liver disease, and high baseline HCV RNA 
with viral relapse. 54% participants with advanced 
liver diseases relaps in this study.14
A network meta-analysis performed by WHO show 
that Sofosbuvir plus Ribavirin in genotype 1 and 4 
HCV infection has SVR12 of 77.26% (95% CI: 67.98 , 
86.54) in treatment-naive and 75.46% (95% CI: 53.94, 
96.98) in treatment-experienced patients.1
This mixed result and the appearance of other more 
effective DAA making the combination of Sofosbuvir 
and Ribavirin is no longer recommended in several 
guidelines for HCV genotype 1. However, Ribavirin is 
widely available and remains to be a treatment option, 
in combination with Sofosbuvir, for genotype 1 HCV 
infection in Indonesia while other DAA’s combinations 
is limited and expensive. 
In this study, 36 patients were treated with 
SOF+RBV+PEG IFN and all patients reached SVR12 
(100%) regardless of the baseline viral load, cirrhosis 
status, co-infection, and duration of therapy (12 and 24 
weeks). Recent systematic review and meta-analysis 
by Dolatimehr et al also showed that combination of 
SOF+RBV+PegIFN is effective for HCV genotype 
1 infection. Total of 5 articles and sample size of 
411 result in 88.54% of pooled SVR rate (95% CI: 
85.77–91.32%).15
Different than the combination of sofosbuvir and 
ribavirin, several studies show relatively similar range 
of effectiveness in sofosbuvir plus peg-interferin plus 
ribavirin combination. In Neutrino phase 3 study, 
SOF+PegIFN+RBV had overall SVR12 of 89% which 
92% in sub genotype 1a and 82% in subgenotype 1b.16 
In HCV TARGET 2.0 study, this regimen had SVR4 
of 85% whereas in TRIO study, this regimen reached 
81% of SVR12.17,18 In these study, cirrhosis status of 
the patients correlated with lower SVR. Despite this 
combination is no longer recommended due to the 
presence of all oral regimen, combination of sofosbuvir 
plus Peg-Interferon plus ribavirin showed excellent 
effectiveness in HVC genotype 1 infections. Moreover, 
this regimen also effective against other unfavorable 
characteristic such as cirrhosis patients, high baseline 
viral load, and co-infection. This regimen is also 
effective both in 12 and 24 weeks of therapy. 
There are some limititation in our study such as no 
complete adverse event data, lack of treatment history 
data, and no data of IL28B which may affect our result. 
We hope that in the future more study will be performed 
with more complete data.
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CONCLUSSION
This study showed that 12 weeks and 24 weeks of 
PegINF+SOF+RBV and SOF+RBV is effective in the 
treatment of genotype 1 chronic hepatitis C infection. 
Despite these regimen is no longer recommended 
in several guidelines, these regimen are effective as 
alternative to all oral DAAs treatment which can be 
difficult to access and expensive in HCV genotype 1 
infection. 
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